RGCC - 'The Greece Test'
RGCC (Research Genetic Cancer Center) aka 'The Greece or Greek Test'
RGCC testing is used for reliable cancer testing and for cancer patients seeking the very best personalized cancer care and integrated cancer treatment therapy.
Personalized cancer testing
• Detect early signs of developing cancer
• Help monitor existing cancers
• Produce an individual profile of chemotherapeutic drugs and natural substances that can be used to achieve the best treatment outcomes
The RGCC test is used as a Personalized Patient-Centered Cancer Care to help those with cancer. This has been in place in Europe for over 14 years. This is not “The Greece Cancer Cure” from Dr. HaritonTzannis Alivizatos of Athens, Greece. We do not profess to cure cancer.
There is a growing interest in personalized cancer treatments and the identification of suitable treatments that may work for each cancer patient. Chemosensitivity testing is one method of doing this. Oncologists primarily rely on the statistical analysis of large treatment trials to decide which drugs to use for specific cancers. Chemosensitivity testing involves testing an individual’s cancer cells in the laboratory to identify which drugs and natural substances demonstrate the best response.
The RGCC Group test is a blood test (or in some cases tissue tests). Tumor cells are identified and isolated from the sample for the following analysis:
• Viability testing of chemotherapy drugs
• Genetic profiling for guidance about targeted therapies e.g. monoclonal antibodies
• Viability testing (and identification of mechanisms of action), of natural substances which may be used as part of a complementary treatment strategy.
The results are presented in a written report which the doctor can use to help guide treatment options and choices. In addition, RGCC Group can provide information about how an individual will ‘handle’ specific chemotherapy agents. Our genetic make-up determines whether we are ‘accumulators’ or ‘rapid metabolizers’ of certain drugs. This can play a critical role in determining how effective a specific treatment is likely to be for us and how significant the side effects will be.
Circulating Tumor Cells
Circulating Tumor Cells (CTCs) are cells that have detached from the primary tumor and flow into the blood or lymphatic circulation creating a secondary tumor. Despite their rare population, these cells exhibit metastatic attributes and are related to cancer progression. Detecting and isolating them is the priority of many research projects and although there has been great progress made in this area there are many drawbacks associated with sensitivity and specificity of different methodologies. RGCC Group has established a new alternative fluidic-based method with 86.6% sensitivity and 83.3% specificity among different types of cancer.
RGCC Groups’s platform, lacking enrichment steps has the ability to offer a precise and accurate detection and isolation of CTCs in blood.
RGCC International GmbH Innovative
Technologies and Services